Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Quadruple Therapy for Post-COVID Smell and Taste Dysfunction
NCT05104424Phase 1Unknown
- Sponsor
- Ministry of Health
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 1, randomised, open-label trial of insulin aspart and gabapentin in Olfactory disorder and taste disorder (2 arms), sponsored by Ministry of Health. Primary endpoints: Evaluation of disturbances of smell and taste (Sniffin' Sticks test) at 4 months, Evaluation of taste disorders at 4 months and 1 more. Status: unknown.
02
Drugs
insulin aspartgabapentin
03
Conditions
Olfactory disordertaste disorder
Beyond the preview
Go deeper on NCT05104424.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104424.